News coverage about Foundation Medicine (NASDAQ:FMI) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Foundation Medicine earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.6540668673708 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
Several research firms have recently weighed in on FMI. ValuEngine raised Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BidaskClub raised Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. Zacks Investment Research raised Foundation Medicine from a “sell” rating to a “hold” rating in a research note on Thursday, February 8th. Finally, Wells Fargo reaffirmed a “market perform” rating and issued a $80.00 price objective (up from $67.00) on shares of Foundation Medicine in a research note on Thursday, March 8th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $69.60.
Shares of NASDAQ FMI traded down $0.75 during midday trading on Friday, hitting $71.50. The stock had a trading volume of 247,614 shares, compared to its average volume of 398,087. The firm has a market capitalization of $2,637.06, a P/E ratio of -15.89 and a beta of -0.13. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.86 and a quick ratio of 1.67. Foundation Medicine has a 1-year low of $30.10 and a 1-year high of $87.10.
Foundation Medicine (NASDAQ:FMI) last released its quarterly earnings results on Wednesday, March 7th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). The company had revenue of $48.90 million for the quarter, compared to analyst estimates of $48.69 million. Foundation Medicine had a negative return on equity of 207.73% and a negative net margin of 105.60%. The business’s revenue was up 69.8% on a year-over-year basis. During the same period last year, the firm posted ($1.02) earnings per share. equities research analysts expect that Foundation Medicine will post -4.33 EPS for the current fiscal year.
In other Foundation Medicine news, Director Michael J. Pellini sold 13,659 shares of Foundation Medicine stock in a transaction that occurred on Tuesday, April 3rd. The stock was sold at an average price of $70.28, for a total transaction of $959,954.52. Following the sale, the director now directly owns 114,211 shares in the company, valued at approximately $8,026,749.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Steven J. Kafka sold 29,791 shares of Foundation Medicine stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $61.55, for a total value of $1,833,636.05. The disclosure for this sale can be found here. Insiders have sold a total of 318,177 shares of company stock worth $21,904,741 over the last three months. 2.70% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/08/foundation-medicine-fmi-earns-media-impact-score-of-0-14.html.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.